BioLineRx BLRX
NASDAQ BLRX
$2.36 +0.00 (+0.00%)
As of: Sep 30, 2026 · 10:05 AM EDT

BioLineRx (BLRX) Total Non-Current Liabilities (2010 - 2026)

Updated

BioLineRx's Total Non-Current Liabilities was $3.18 million in the quarter ended Jun 30, 2026, down 58.8% from $7.72 million a year earlier and down 26.6% from the prior quarter.

Analysis

BioLineRx (BLRX) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends

As of Dec 31, 2025, Total Non-Current Liabilities at BioLineRx came in at $5.44 million, down 45.8% from the prior year.

  • Total Non-Current Liabilities shows a five-year compound annual growth rate of -17.9% (years ended Dec 2020 to Dec 2025).
  • In earlier years, Total Non-Current Liabilities was $10.04 million in the year ended Dec 31, 2024 (+26.8%), $7.92 million in the year ended Dec 31, 2023 (+462.4%), $1.41 million in the year ended Dec 31, 2022 (+44.4%) and $975,000 in the year ended Dec 31, 2021 (-93.3%).
  • The figure for the quarter ended Jun 30, 2026 marks the lowest quarterly Total Non-Current Liabilities since the quarter ended Dec 31, 2022.
  • Compared with a year earlier, Total Non-Current Liabilities has declined for five straight quarters, with an average decline of 32.2% over the last eight quarters.
  • The best year-over-year quarter for Total Non-Current Liabilities over five years was the quarter ended Mar 31, 2023 (growth of 673.3%); the worst was the quarter ended Dec 31, 2021 (a decline of 93.3%).
  • Per Business Quant data, BLRX's Total Non-Current Liabilities in the three quarters before the quarter ended Jun 30, 2026 was $4.34 million (quarter ended Mar 31, 2026), $5.44 million (quarter ended Dec 31, 2025) and $6.6 million (quarter ended Sep 30, 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 105.99 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 106.45 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 80.25 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 48.34 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -967.00 Mn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 81.11 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 36.04 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 100.86 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 5.92 Bn
10 BioLineRx 6.34 Bn 6.35 Bn 235,000.00 3.18 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.18 Mn
Mar 31, 2026 4.34 Mn
Dec 31, 2025 5.44 Mn
Sep 30, 2025 6.60 Mn
Jun 30, 2025 7.72 Mn
Mar 31, 2025 8.62 Mn
Dec 31, 2024 10.04 Mn
Sep 30, 2024 19.28 Mn
Jun 30, 2024 20.10 Mn
Mar 31, 2024 7.17 Mn
Dec 31, 2023 7.92 Mn
Sep 30, 2023 25.00 Mn
Jun 30, 2023 25.44 Mn
Mar 31, 2023 17.49 Mn
Dec 31, 2022 1.41 Mn
Sep 30, 2022 18.02 Mn
Jun 30, 2022 1.64 Mn
Mar 31, 2022 2.26 Mn
Dec 31, 2021 975,000.00
Sep 30, 2021 5.69 Mn
API Access

BioLineRx Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=BLRX&period=max&api_key=YOUR_API_KEY